Highlights

  • Avon Technologies shares at GBX 1,760 on 30 January 2026, down 1.57% intraday.
  • Jefferies and Investec issue buy ratings with target prices of GBX 2,330 and GBX 2,350.
  • Q1 FY26 performance saw stable group momentum, with Team Wendy affected by U.S. government shutdown delays but operational gearing supporting future growth.

Avon Technologies plc (LSE:AVON) shares have been attracting analysts’ attention recently, with Jefferies and Investec Bank (UK) plc issued buy ratings with target prices of GBX 2,330 and GBX 2,350, respectively.

The rating might follow the management’s commentary released in the first quarter trading update for FY26 that highlight that the company is likely to exceed its FY26 financial targets.

Jos Sclater, Chief Executive Officer, commented:

“Having stabilised, strengthened and transformed Avon over the last three years, 2026 will see an increased focus on the growth stage of our strategy. We are investing across key programmes and new products that will strengthen our competitive position and expand our addressable markets.  We are already seeing some promising early results.

We remain on track to meet or exceed our FY26 financial targets and look forward to sharing the next phase of our strategic development alongside our Interim and Full Year results."

Furthermore, ahead of its Annual General Meeting in Melksham, the group highlighted ongoing demand for its CBRN (Chemical, Biological, Radiological, and Nuclear) protection products and updates from its Team Wendy division.

Q1 Trading Update Highlights

The company reported a positive start to FY26 at the group level, with sustained demand for protective technologies supporting operations and a healthy order book. While the Team Wendy segment experienced a slower first quarter, this was linked to a U.S. government shutdown, which delayed product testing and federal deliveries.

Revenue from the U.S. Department of War and other federal sources was lower than anticipated, with margins affected by planned investment to ramp production in Q2. Group-wide forecasts remain in line with guidance provided at the FY25 results, supported by ongoing demand for Avon’s CBRN protection and other protective solutions.

Segment Performance

CBRN Protection Products: Demand remained high for the group’s chemical, biological, radiological, and nuclear protection equipment, maintaining operational momentum and a solid sales pipeline.

Team Wendy Division: Order volumes remained strong, but revenue in Q1 was impacted by delayed government approvals and testing. Planned production ramp-ups and inventory adjustments are expected to support higher revenue in subsequent quarters, assuming no further disruptions.

Operational Efficiency: Across the group, operational gearing and order fulfilment capacity contributed to overall revenue performance, with strategic investment ahead of production scaling in key facilities.

Broker Ratings and Market Impact

Jefferies maintained a buy rating with a target price of GBX 2,330, while Investec Bank (UK) plc issued a buy rating with a target of GBX 2,350.

Shares traded at GBX 1,760 at the time of writing, down 28 points or 1.57% intraday, with broker support pointing to potential upside of roughly 32–34% based on the target prices.